Alvos moleculares e celulares do extrato padronizado de Ginkgo biloba L. na supressão condicionada
Autor(a) principal: | |
---|---|
Data de Publicação: | 2017 |
Tipo de documento: | Tese |
Idioma: | por |
Título da fonte: | Repositório Institucional da UNIFESP |
Texto Completo: | https://sucupira.capes.gov.br/sucupira/public/consultas/coleta/trabalhoConclusao/viewTrabalhoConclusao.jsf?popup=true&id_trabalho=5615974 http://repositorio.unifesp.br/handle/11600/50210 |
Resumo: | The present study investigated the effect of the standardized extract of Ginkgo biloba (EGb) on the steps steps in the memory of fear and the extinction of fear memory. A proposal of foundations in multiple dose doses of extract; different times of treatment and acquisition of extract products; different times of treatment and pharmacological acquisitions by agonists and antagonists of serotonergic type 1A (5-HT1AR), glutamatergic receptors NMDA-type, 2B subunit (GluN2B-NMDA) and GABAA (GABAAR, α1 and α5 subunit) in animals submitted to the chest paradigm, assessed by conditioned suppression rate of licking response. Furthermore, we evaluated changes in gene expression (mRNA and protein) in the dorsal hippocampal formation, the amygdaloid complex, and the prefrontal cortex. Behavioral data suggest an EGb time and dose-dependent effect on modulation of 5-HT1A, GABAA and GluN2B-NMDA receptors as well as a glial fibial acidic protein (GFAP). The behavioural data from conditioned suppression ratio allow us to propose the effect of EGb as a nootropic agent because, in addition to not prevent the acquisition of fear memory, it modulates in a dose-dependent manner the extinction of conditioned fear. Our results show for the first time that the menmonic effect of EGb is correlated with differential expression of GluN2B-NMDA, GABAA-α1, GABAA-α5 receptors and GFAP in the dorsal hippocampal (DHF) and 5-HT1AR receptors in the layer CA3 of hippocampus. However, that either activation of GABAARs (Diazepam) or blocking of GluN2B-NMDAR (Ro 25-6981) or 5-HT1AR ((S) -WAY100135) resulted in impairment in memory acquisition and that treatment with high doses of EGb reversed the deficit by increasing the expression of GluN2B and/or GABAAR-α1 and α5 simultaneously in the CA1 region of the hippocampus. Our data added new insights into the role of α1 and α5 subunits of GABAA and GluN2B-NMDA receptors in DHF as an EGb target. In addition, they point to a parallel involvement of these receptors in the prelimbic (PrL) and infralimbic (IL) areas of the prefrontal cortex (PFC) in the acquisition of conditioned suppression, where acquisition impairment was associated with reduced GluN2B-NMDAR and GABAAR α1 expression in PrL. Furthermore, for the first time in the literature, it shows a colocalization between glutamatergic receptors and astrocytes after treatment with EGb. Our studies have analyze the fear memory extinction through the behavioral and pharmacology approach using selective antagonists administered prior to EGb treatment at the different stages of extinction (training and testing) that provide original data on the effects of EGb as well as in the spontaneous recovery of conditioned fear (Zamberlam et al, 2016). We have shown that treatment with Ro25-6981, given prior to conditioning or prior to extinction training, prevented spontaneous recovery of fear memory reported for EGb 1.0 g.Kg-1. However, treatment with (S)-WAY 100135 or Picrotoxin (GABAA-selective antagonist) prevented the effects of EGb (0.25 or 1.0 g.Kg-1) when administered prior to extinction training. We found decreasing of relative expression of Gabra1 and Gfap and increase of Gabra5 in the DHF of the groups treated with antagonists Ro 256981 and Picrotoxin (GABAA). Our data suggest that the increased Gabra5 seems related with impaired extinction of fear memory. In the prefrontal cortex, a regulation of the receptors seems to occur in the opposite way. Data from the gene expression to groups treated with Ro 25-6981 and (S)-WAY 100135 antagonists suggest that increased in Gabra1 expression in the PFC seems to be associated with fear extinction memory. The results suggest that the effects of EGb are multitarget and depend on the interaction between receptors in a dose-dependent manner. Then, our data suggest that spontaneous recovery is not modulated by gene expression of Grin2b, Gabra1, Gabra5, Htr1a and Gfap in the cenamygdaloid complex. However, modulates diferentially the protein expression in Ce and BLA in the extinction fear memory and spontaneous recover of fear memory. Taken together, our data suggest that the serotonergic, glutamatergic and GABAergic receptors analyzed in this study, as well as astrocytes, are targets of the effects of the standardized extract of Ginkgo biloba on the acquisition and extinction of conditioned suppression in a tissue-dose-time-dependent manner. |
id |
UFSP_7a68b934407a21c8255e7b173bdc22a2 |
---|---|
oai_identifier_str |
oai:repositorio.unifesp.br/:11600/50210 |
network_acronym_str |
UFSP |
network_name_str |
Repositório Institucional da UNIFESP |
repository_id_str |
3465 |
spelling |
Alvos moleculares e celulares do extrato padronizado de Ginkgo biloba L. na supressão condicionadaCellular and molecular targets of the standardized extract of Ginkgo biloba L. in conditioned suppressionGinkgo bilobaMemory5-Ht1ArGabaarGlun2B-NmdarGinkgo bilobaMemória5-Ht1ArGabaarGlun2B-NmdarThe present study investigated the effect of the standardized extract of Ginkgo biloba (EGb) on the steps steps in the memory of fear and the extinction of fear memory. A proposal of foundations in multiple dose doses of extract; different times of treatment and acquisition of extract products; different times of treatment and pharmacological acquisitions by agonists and antagonists of serotonergic type 1A (5-HT1AR), glutamatergic receptors NMDA-type, 2B subunit (GluN2B-NMDA) and GABAA (GABAAR, α1 and α5 subunit) in animals submitted to the chest paradigm, assessed by conditioned suppression rate of licking response. Furthermore, we evaluated changes in gene expression (mRNA and protein) in the dorsal hippocampal formation, the amygdaloid complex, and the prefrontal cortex. Behavioral data suggest an EGb time and dose-dependent effect on modulation of 5-HT1A, GABAA and GluN2B-NMDA receptors as well as a glial fibial acidic protein (GFAP). The behavioural data from conditioned suppression ratio allow us to propose the effect of EGb as a nootropic agent because, in addition to not prevent the acquisition of fear memory, it modulates in a dose-dependent manner the extinction of conditioned fear. Our results show for the first time that the menmonic effect of EGb is correlated with differential expression of GluN2B-NMDA, GABAA-α1, GABAA-α5 receptors and GFAP in the dorsal hippocampal (DHF) and 5-HT1AR receptors in the layer CA3 of hippocampus. However, that either activation of GABAARs (Diazepam) or blocking of GluN2B-NMDAR (Ro 25-6981) or 5-HT1AR ((S) -WAY100135) resulted in impairment in memory acquisition and that treatment with high doses of EGb reversed the deficit by increasing the expression of GluN2B and/or GABAAR-α1 and α5 simultaneously in the CA1 region of the hippocampus. Our data added new insights into the role of α1 and α5 subunits of GABAA and GluN2B-NMDA receptors in DHF as an EGb target. In addition, they point to a parallel involvement of these receptors in the prelimbic (PrL) and infralimbic (IL) areas of the prefrontal cortex (PFC) in the acquisition of conditioned suppression, where acquisition impairment was associated with reduced GluN2B-NMDAR and GABAAR α1 expression in PrL. Furthermore, for the first time in the literature, it shows a colocalization between glutamatergic receptors and astrocytes after treatment with EGb. Our studies have analyze the fear memory extinction through the behavioral and pharmacology approach using selective antagonists administered prior to EGb treatment at the different stages of extinction (training and testing) that provide original data on the effects of EGb as well as in the spontaneous recovery of conditioned fear (Zamberlam et al, 2016). We have shown that treatment with Ro25-6981, given prior to conditioning or prior to extinction training, prevented spontaneous recovery of fear memory reported for EGb 1.0 g.Kg-1. However, treatment with (S)-WAY 100135 or Picrotoxin (GABAA-selective antagonist) prevented the effects of EGb (0.25 or 1.0 g.Kg-1) when administered prior to extinction training. We found decreasing of relative expression of Gabra1 and Gfap and increase of Gabra5 in the DHF of the groups treated with antagonists Ro 256981 and Picrotoxin (GABAA). Our data suggest that the increased Gabra5 seems related with impaired extinction of fear memory. In the prefrontal cortex, a regulation of the receptors seems to occur in the opposite way. Data from the gene expression to groups treated with Ro 25-6981 and (S)-WAY 100135 antagonists suggest that increased in Gabra1 expression in the PFC seems to be associated with fear extinction memory. The results suggest that the effects of EGb are multitarget and depend on the interaction between receptors in a dose-dependent manner. Then, our data suggest that spontaneous recovery is not modulated by gene expression of Grin2b, Gabra1, Gabra5, Htr1a and Gfap in the cenamygdaloid complex. However, modulates diferentially the protein expression in Ce and BLA in the extinction fear memory and spontaneous recover of fear memory. Taken together, our data suggest that the serotonergic, glutamatergic and GABAergic receptors analyzed in this study, as well as astrocytes, are targets of the effects of the standardized extract of Ginkgo biloba on the acquisition and extinction of conditioned suppression in a tissue-dose-time-dependent manner.O presente estudo investigou o efeito do extrato padronizado de Ginkgo biloba (EGb) nas distintas etapas da memória do medo condicionado e da extinção da memória do medo. A proposta foi fundamentanda em esquemas de múltiplas doses do extrato, diferentes tempos de tratamento (aquisição e evocação) e intervenções farmacológicas, por meio de agonistas e antagonistas dos receptores serotoninérgicos do tipo 1A (5-HT1AR), glutamatérgicos do tipo NMDA, subunidade 2B (GluN2B-NMDA) e GABAérgicos do tipo GABAA (GABAAR, subunidade α1 e α5) em animais submetidos ao paradigma de medo condicionado, avaliado pela taxa de supressão condicionada da resposta de lamber. Ainda, avaliamos as mudanças na expressão do produto gêncio (mRNA e proteína) em na formação hipocampal dorsal, complexo amigdaloide e córtex pré-frontal. Os dados comportamentais sugerem um efeito dependente do tempo de administração e da dose do EGb na modulação dos receptores 5-HT1A, GABAA e GluN2B-NMDA bem como a proteína ácida fibrilar glial (GFAP). Ainda, dados nos possibilitam propor o efeito do EGb como agente nootrópico pois, além de não impedir a aquisição e a extinção, o seu uso favorece a evocação da memória de supressão condicionada, sugerindo seu uso em tratamentos de declínio de memória. Adicionalmente, nossos resultados mostram, pela primeira vez, que o efeito menemônico do EGb é decorrente da expressão diferencial dos receptores GluN2B-NMDA, GABAA-α1, GABAA-α5 e de GFAP na formação hipocampal dorsal (FHD) e de 5-HT1AR na camada CA3 do hipocampo e mostraram, ainda, que tanto a ativação de GABAARs (Diazepam) ou o bloqueio farmacológico de GluN2B-NMDAR (Ro 25-6981) ou de 5-HT1AR ((S)-WAY100135) resultou em prejuízo na memória, e que o tratamento com altas doses de EGb reverteu o déficit através do aumento da expressão de GluN2B e/ou de GABAAR-α1 e α5 simultaneamente na região CA1 do hipocampo. Nossos dados adicionam novos conhecimentos sobre o papel das subunidades α1 e α5 dos receptores GABAA e de GluN2B-NMDA na FHD como um alvo do EGb. Também descrevem o envolvimento dos receptores GluN2B-NMDA e GABAAR α1 no córtex prélimbico (PrL) na aquisição da supressão condicionada, onde o prejuízo verificado na aquisição foi associado com redução na expressão desses receptores no PrL. Os dados mostram pela primeira vez que o tratamento com EGb resultou na expressão de GluN2B-NMDAR em astrócitos no PrL. Entretanto, quando avaliamos o efeito do tratamento com EGb após bloqueio dos receptores em estudo, antes do condicionamento ou antes do treino da extinção, verificamos que o tratamento com Ro25-6981, impediu a recuperação espontânea (reaparecimento) da memória do medo relatada para EGb 1.0 g.Kg-1. Entretanto, o tratamento com (S)-WAY 100135 ou Picrotoxina (antagonista seletivo para GABAA) antes do treino da extinção, impediu os efeitos de EGb (0.25 ou 1.0 g.Kg-1). Os achados comportamentais foram associados à redução na expressão relativa de Gabra1 e Gfap e aumento de Gabra5 na FHD, sugerindo que o aumento da expressão de Gabra5 parece estar associada a um prejuízo na extinção. Ainda, no CPF a regulação desses receptores parece ocorrer de forma oposta ao verificado na FHD. O tratamento com antagonistas Ro 25-6981 e (S)-WAY 100135 evidenciou que os efeitos do tratamento com EGb na extinção da memória do medo parece ser associado a um aumento da expressão de Gabra1 no CPF. Os dados de expressão gênica no complexo amigdaloide corroboram com achadoa anteriore sobre os efeitos do EGb, os quais parecem ser mutialvos e depedem da interação entre os receptores de maneira dependente da dose. Ainda, que a recuperação espontânea da memória do medo parece não estar associada as modificações da expressão de GluN2B-NMDA, GABAA-α1, GABAA-α5, 5-HT1AR e GFAP no complexo amigdaloide. Entretanto, o EGb modula diferencialmente a expressão de proteínas nos núcleos CE e BLA do complexo amigdaloide durante a extinção do medo condicionado e na recuperação espontânea da memória do medo. Em conjunto, nossos dados sugerem que os receptores serotoninérgicos, glutamatérgicos e GABAérgicos analisados neste estudo, bem como os astrócitos são alvos dos efeitos do extrato padronizado de Ginkgo biloba na aquisição e na extinção da supressão condicionada de maneira tecido-dose-tempo-dependente.Dados abertos - Sucupira - Teses e dissertações (2017)Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (CAPES)Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP)Universidade Federal de São Paulo (UNIFESP)Cerutti, Suzete Maria [UNIFESP]Cerutti, Janete Maria [UNIFESP]http://lattes.cnpq.br/1384038091754225http://lattes.cnpq.br/9076343601956182http://lattes.cnpq.br/4400354066404536Universidade Federal de São Paulo (UNIFESP)Zamberlam, Claudia Raquel [UNIFESP]2019-06-19T14:57:35Z2019-06-19T14:57:35Z2017-11-27info:eu-repo/semantics/doctoralThesisinfo:eu-repo/semantics/publishedVersion391 f.application/pdfhttps://sucupira.capes.gov.br/sucupira/public/consultas/coleta/trabalhoConclusao/viewTrabalhoConclusao.jsf?popup=true&id_trabalho=5615974http://repositorio.unifesp.br/handle/11600/50210porSão Pauloinfo:eu-repo/semantics/openAccessreponame:Repositório Institucional da UNIFESPinstname:Universidade Federal de São Paulo (UNIFESP)instacron:UNIFESP2024-08-10T11:57:51Zoai:repositorio.unifesp.br/:11600/50210Repositório InstitucionalPUBhttp://www.repositorio.unifesp.br/oai/requestbiblioteca.csp@unifesp.bropendoar:34652024-08-10T11:57:51Repositório Institucional da UNIFESP - Universidade Federal de São Paulo (UNIFESP)false |
dc.title.none.fl_str_mv |
Alvos moleculares e celulares do extrato padronizado de Ginkgo biloba L. na supressão condicionada Cellular and molecular targets of the standardized extract of Ginkgo biloba L. in conditioned suppression |
title |
Alvos moleculares e celulares do extrato padronizado de Ginkgo biloba L. na supressão condicionada |
spellingShingle |
Alvos moleculares e celulares do extrato padronizado de Ginkgo biloba L. na supressão condicionada Zamberlam, Claudia Raquel [UNIFESP] Ginkgo biloba Memory 5-Ht1Ar Gabaar Glun2B-Nmdar Ginkgo biloba Memória 5-Ht1Ar Gabaar Glun2B-Nmdar |
title_short |
Alvos moleculares e celulares do extrato padronizado de Ginkgo biloba L. na supressão condicionada |
title_full |
Alvos moleculares e celulares do extrato padronizado de Ginkgo biloba L. na supressão condicionada |
title_fullStr |
Alvos moleculares e celulares do extrato padronizado de Ginkgo biloba L. na supressão condicionada |
title_full_unstemmed |
Alvos moleculares e celulares do extrato padronizado de Ginkgo biloba L. na supressão condicionada |
title_sort |
Alvos moleculares e celulares do extrato padronizado de Ginkgo biloba L. na supressão condicionada |
author |
Zamberlam, Claudia Raquel [UNIFESP] |
author_facet |
Zamberlam, Claudia Raquel [UNIFESP] |
author_role |
author |
dc.contributor.none.fl_str_mv |
Cerutti, Suzete Maria [UNIFESP] Cerutti, Janete Maria [UNIFESP] http://lattes.cnpq.br/1384038091754225 http://lattes.cnpq.br/9076343601956182 http://lattes.cnpq.br/4400354066404536 Universidade Federal de São Paulo (UNIFESP) |
dc.contributor.author.fl_str_mv |
Zamberlam, Claudia Raquel [UNIFESP] |
dc.subject.por.fl_str_mv |
Ginkgo biloba Memory 5-Ht1Ar Gabaar Glun2B-Nmdar Ginkgo biloba Memória 5-Ht1Ar Gabaar Glun2B-Nmdar |
topic |
Ginkgo biloba Memory 5-Ht1Ar Gabaar Glun2B-Nmdar Ginkgo biloba Memória 5-Ht1Ar Gabaar Glun2B-Nmdar |
description |
The present study investigated the effect of the standardized extract of Ginkgo biloba (EGb) on the steps steps in the memory of fear and the extinction of fear memory. A proposal of foundations in multiple dose doses of extract; different times of treatment and acquisition of extract products; different times of treatment and pharmacological acquisitions by agonists and antagonists of serotonergic type 1A (5-HT1AR), glutamatergic receptors NMDA-type, 2B subunit (GluN2B-NMDA) and GABAA (GABAAR, α1 and α5 subunit) in animals submitted to the chest paradigm, assessed by conditioned suppression rate of licking response. Furthermore, we evaluated changes in gene expression (mRNA and protein) in the dorsal hippocampal formation, the amygdaloid complex, and the prefrontal cortex. Behavioral data suggest an EGb time and dose-dependent effect on modulation of 5-HT1A, GABAA and GluN2B-NMDA receptors as well as a glial fibial acidic protein (GFAP). The behavioural data from conditioned suppression ratio allow us to propose the effect of EGb as a nootropic agent because, in addition to not prevent the acquisition of fear memory, it modulates in a dose-dependent manner the extinction of conditioned fear. Our results show for the first time that the menmonic effect of EGb is correlated with differential expression of GluN2B-NMDA, GABAA-α1, GABAA-α5 receptors and GFAP in the dorsal hippocampal (DHF) and 5-HT1AR receptors in the layer CA3 of hippocampus. However, that either activation of GABAARs (Diazepam) or blocking of GluN2B-NMDAR (Ro 25-6981) or 5-HT1AR ((S) -WAY100135) resulted in impairment in memory acquisition and that treatment with high doses of EGb reversed the deficit by increasing the expression of GluN2B and/or GABAAR-α1 and α5 simultaneously in the CA1 region of the hippocampus. Our data added new insights into the role of α1 and α5 subunits of GABAA and GluN2B-NMDA receptors in DHF as an EGb target. In addition, they point to a parallel involvement of these receptors in the prelimbic (PrL) and infralimbic (IL) areas of the prefrontal cortex (PFC) in the acquisition of conditioned suppression, where acquisition impairment was associated with reduced GluN2B-NMDAR and GABAAR α1 expression in PrL. Furthermore, for the first time in the literature, it shows a colocalization between glutamatergic receptors and astrocytes after treatment with EGb. Our studies have analyze the fear memory extinction through the behavioral and pharmacology approach using selective antagonists administered prior to EGb treatment at the different stages of extinction (training and testing) that provide original data on the effects of EGb as well as in the spontaneous recovery of conditioned fear (Zamberlam et al, 2016). We have shown that treatment with Ro25-6981, given prior to conditioning or prior to extinction training, prevented spontaneous recovery of fear memory reported for EGb 1.0 g.Kg-1. However, treatment with (S)-WAY 100135 or Picrotoxin (GABAA-selective antagonist) prevented the effects of EGb (0.25 or 1.0 g.Kg-1) when administered prior to extinction training. We found decreasing of relative expression of Gabra1 and Gfap and increase of Gabra5 in the DHF of the groups treated with antagonists Ro 256981 and Picrotoxin (GABAA). Our data suggest that the increased Gabra5 seems related with impaired extinction of fear memory. In the prefrontal cortex, a regulation of the receptors seems to occur in the opposite way. Data from the gene expression to groups treated with Ro 25-6981 and (S)-WAY 100135 antagonists suggest that increased in Gabra1 expression in the PFC seems to be associated with fear extinction memory. The results suggest that the effects of EGb are multitarget and depend on the interaction between receptors in a dose-dependent manner. Then, our data suggest that spontaneous recovery is not modulated by gene expression of Grin2b, Gabra1, Gabra5, Htr1a and Gfap in the cenamygdaloid complex. However, modulates diferentially the protein expression in Ce and BLA in the extinction fear memory and spontaneous recover of fear memory. Taken together, our data suggest that the serotonergic, glutamatergic and GABAergic receptors analyzed in this study, as well as astrocytes, are targets of the effects of the standardized extract of Ginkgo biloba on the acquisition and extinction of conditioned suppression in a tissue-dose-time-dependent manner. |
publishDate |
2017 |
dc.date.none.fl_str_mv |
2017-11-27 2019-06-19T14:57:35Z 2019-06-19T14:57:35Z |
dc.type.driver.fl_str_mv |
info:eu-repo/semantics/doctoralThesis |
dc.type.status.fl_str_mv |
info:eu-repo/semantics/publishedVersion |
format |
doctoralThesis |
status_str |
publishedVersion |
dc.identifier.uri.fl_str_mv |
https://sucupira.capes.gov.br/sucupira/public/consultas/coleta/trabalhoConclusao/viewTrabalhoConclusao.jsf?popup=true&id_trabalho=5615974 http://repositorio.unifesp.br/handle/11600/50210 |
url |
https://sucupira.capes.gov.br/sucupira/public/consultas/coleta/trabalhoConclusao/viewTrabalhoConclusao.jsf?popup=true&id_trabalho=5615974 http://repositorio.unifesp.br/handle/11600/50210 |
dc.language.iso.fl_str_mv |
por |
language |
por |
dc.rights.driver.fl_str_mv |
info:eu-repo/semantics/openAccess |
eu_rights_str_mv |
openAccess |
dc.format.none.fl_str_mv |
391 f. application/pdf |
dc.coverage.none.fl_str_mv |
São Paulo |
dc.publisher.none.fl_str_mv |
Universidade Federal de São Paulo (UNIFESP) |
publisher.none.fl_str_mv |
Universidade Federal de São Paulo (UNIFESP) |
dc.source.none.fl_str_mv |
reponame:Repositório Institucional da UNIFESP instname:Universidade Federal de São Paulo (UNIFESP) instacron:UNIFESP |
instname_str |
Universidade Federal de São Paulo (UNIFESP) |
instacron_str |
UNIFESP |
institution |
UNIFESP |
reponame_str |
Repositório Institucional da UNIFESP |
collection |
Repositório Institucional da UNIFESP |
repository.name.fl_str_mv |
Repositório Institucional da UNIFESP - Universidade Federal de São Paulo (UNIFESP) |
repository.mail.fl_str_mv |
biblioteca.csp@unifesp.br |
_version_ |
1814268340632289280 |